Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Not Confirmed
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Not Confirmed
Not Confirmed
12-14 January, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Tides Asia
Not Confirmed
Contact SupplierTides Asia
Industry Trade Show
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Industry Trade Show
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Industry Trade Show
Not Confirmed
12-14 January, 2026
Digital content
NEWS #PharmaBuzz
02 Dec 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251202393269/en/CatalYm-Announces-First-Patient-Dosed-in-Phase-2b-Trial-Evaluating-Visugromab-in-Combination-with-Chemoimmunotherapy-as-Second-Line-Treatment-in-Metastatic-Non-squamous-NSCLC
20 Oct 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251020679539/en/CatalYm-Presents-Long-Term-Phase-12a-Data-Confirming-Sustained-Responses-with-Visugromab-in-CPI-Refractory-Tumors-at-ESMO-2025
17 Oct 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251017483380/en/CatalYm-Presents-Phase-2-Data-in-Neoadjuvant-Bladder-Cancer-Demonstrating-Substantial-Increase-of-Anti-Tumor-Activity-for-Visugromab-in-Combination-with-PD-1-Inhibitor-at-ESMO
30 Sep 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250930495985/en/CatalYm-Announces-First-Patient-Dosed-in-Phase-2b-Trial-Evaluating-Visugromab-in-Combination-with-Chemoimmunotherapy-as-First-Line-Treatment-in-Metastatic-Non-squamous-NSCLC
22 Sep 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250922505063/en/CatalYm-to-Present-Primary-Results-From-Phase-2-Neoadjuvant-Bladder-Cancer-Trial-in-Late-breaking-Oral-Presentation-at-ESMO
15 Sep 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250915985602/en/CatalYm-Announces-Leadership-Changes-to-Accelerate-Visugromab-Late-stage-Clinical-Development
Drugs in Development
Details:
Visugromab is a antibody candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Lead Product(s): Visugromab,Nivolumab,Docetaxel
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 24, 2025
Details : Visugromab is a antibody candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
November 24, 2025
Details:
CTL-002 (visugromab) is a antibody drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Carcinoma, Hepatocellular.
Lead Product(s): Visugromab,Nivolumab
Therapeutic Area: Oncology Brand Name: CTL-002
Study Phase: Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 21, 2025
Visugromab, Nivolumab, TKI vs Placebo in Metastatic Liver Cancer
Details : CTL-002 (visugromab) is a antibody drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Carcinoma, Hepatocellular.
Product Name : CTL-002
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
October 21, 2025
Details:
Visugromab is a Antibody drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Cancer Cachexia.
Lead Product(s): Visugromab
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase II/ Phase IIIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 08, 2025
Lead Product(s) : Visugromab
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Visugromab in Cachexia International Trial
Details : Visugromab is a Antibody drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Cancer Cachexia.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
August 08, 2025
Details:
Visugromab is a Antibody drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Lead Product(s): Visugromab,Pembrolizumab,Pemetrexed,Carboplatin
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 01, 2025
Lead Product(s) : Visugromab,Pembrolizumab,Pemetrexed,Carboplatin
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Visugromab + Immunochemotherapy In 1L Metastatic NSCLC
Details : Visugromab is a Antibody drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
August 01, 2025
Details:
The Proceeds will expand CTL-002 (visugromab) late-stage clinical development into earlier lines of treatment in combination with nivolumab for the treatment of bladder cancer.
Lead Product(s): Visugromab,Nivolumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Canaan Partners
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Series D Financing July 16, 2024
Lead Product(s) : Visugromab,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Canaan Partners
Deal Size : $150.0 million
Deal Type : Series D Financing
CatalYm cashes in on early-stage cancer data with $150M series D
Details : The Proceeds will expand CTL-002 (visugromab) late-stage clinical development into earlier lines of treatment in combination with nivolumab for the treatment of bladder cancer.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
July 16, 2024
Details:
CTL-002 (visugromab) is a monoclonal antibody that neutralizes GDF-15 is being investigated in combination with nivolumab, a PD-1 inhibitor) in R/R non-small cell lung cancer (MIBC).
Lead Product(s): Visugromab,Nivolumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 02, 2024
Lead Product(s) : Visugromab,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
CatalYm Reports Lasting Responses in Late-Line NSCLC and Other Cancer Patients
Details : CTL-002 (visugromab) is a monoclonal antibody that neutralizes GDF-15 is being investigated in combination with nivolumab, a PD-1 inhibitor) in R/R non-small cell lung cancer (MIBC).
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
June 02, 2024
Details:
CTL-002 (Visugromab) is a monoclonal antibody that neutralizes the tumor-derived Growth Differentiation Factor-15 (GDF-15) in combination with neoadjuvant immunotherapy (nivolumab, aPD-1 inhibitor) in muscle invasive bladder cancer (MIBC).
Lead Product(s): Visugromab,Nivolumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 26, 2023
Details : CTL-002 (Visugromab) is a monoclonal antibody that neutralizes the tumor-derived Growth Differentiation Factor-15 (GDF-15) in combination with neoadjuvant immunotherapy (nivolumab, aPD-1 inhibitor) in muscle invasive bladder cancer (MIBC).
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
October 26, 2023
Details:
Nivolumab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Urinary Bladder Neoplasms.
Lead Product(s): Nivolumab,Visugromab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 28, 2023
Details : Nivolumab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Urinary Bladder Neoplasms.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
September 28, 2023
Details:
The financing will support the continued, promising clinical development of its lead candidate, visugromab, a humanized monoclonal antibody engineered to neutralize the tumor-produced Growth Differentiation Factor-15 (GDF-15).
Lead Product(s): Visugromab,Nivolumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Brandon Capital
Deal Size: $51.8 million Upfront Cash: Undisclosed
Deal Type: Series C Financing November 22, 2022
Lead Product(s) : Visugromab,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Brandon Capital
Deal Size : $51.8 million
Deal Type : Series C Financing
Details : The financing will support the continued, promising clinical development of its lead candidate, visugromab, a humanized monoclonal antibody engineered to neutralize the tumor-produced Growth Differentiation Factor-15 (GDF-15).
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
November 22, 2022
Details:
Visugromab, formerly known as CTL-002, is a monoclonal antibody that neutralizes GDF-15, a key immunosuppressor, which has been shown to prevent T cell migration into tumors, enabling cancerous cells to evade the immune system.
Lead Product(s): Visugromab,Nivolumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 26, 2022
Lead Product(s) : Visugromab,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Visugromab, formerly known as CTL-002, is a monoclonal antibody that neutralizes GDF-15, a key immunosuppressor, which has been shown to prevent T cell migration into tumors, enabling cancerous cells to evade the immune system.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
September 26, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Share 
